Over the past 18 months, the Self-Monitoring Blood Glucose (SMBG) Devices industry trends have pivoted toward integrated digital ecosystems. In March 2024, Abbott and Dexcom announced a strategic data-sharing pact that will allow users to toggle between Libre and G6/G7 readings within a single clinician portal, setting the stage for interoperable CGM-SMBG hybrids. Medtronic’s $1.2 billion acquisition of wearable insulin-titration startup CeQur in Q1 2024 is accelerating patch-pump-plus-strip bundles aimed at Type 2 patients who prefer pen therapy but want algorithmic guidance. Meanwhile, Roche launched the Accu-Chek Axle in the EU—an NFC-enabled meter that auto-uploads dosing data to the mySugr app and reimburses strips via a value-based subscription pilot with German insurers; early adherence is up 18%. On the regulatory front, the FDA’s draft guidance (Jan 2024) reclassifies Bluetooth-enabled meters as Class II devices with streamlined 510(k) pathways, cutting review time to ~90 days and spurring a wave of start-ups: GlucoPure closed a $22 million Series A in April to scale a phone-case-integrated strip dock targeting emerging markets, while SugarCube expanded Indian production capacity by 40% after receiving CE-IVDR certification in December 2023. Consumer behavior is shifting toward discreet, subscription-based consumables: Amazon Pharmacy’s SMBG auto-refill bundles grew 35% YoY, and private-label strips now account for 11% of U.S. retail volume, pressuring legacy players to bundle coaching services. Looking ahead, expect further consolidation around data-centric platforms and tiered pricing models as payers tie reimbursement to validated time-in-range improvements.
